Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Bailey

Interventional Cardiology Shreveport, LA Medical Doctor

NPI 1003921909 CMS profile 90994

1541 Kings Hwy, Shreveport, LA 71103

Open in the dashboard

General payments

$305,384

207 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,025 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Steven Bailey of Shreveport, LA is reported in the CMS Open Payments database as having received $305,384 across 207 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,025 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $57,662 23
2024 General $60,781 23
2023 General $61,434 19
2022 General $35,726 29
2021 General $22,857 22
2020 General $14,550 12
2019 General $52,375 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Bailey
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Steven Bailey were reported at $57,662. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Steven Bailey Interventional Cardiology median Middle half National median
2019 $52,375 $1,097 $329–$3,048 $163
2020 $14,550 $473 $161–$1,480 $114
2021 $22,857 $677 $233–$1,827 $132
2022 $35,726 $978 $333–$2,724 $149
2023 $61,434 $1,136 $382–$2,986 $160
2024 $60,781 $1,181 $395–$3,326 $164
2025 $57,662 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $233,645 121 payments
  2. JenaValve Technology, Inc. $51,698 16 payments
  3. Boston Scientific Corporation $18,578 13 payments
  4. Medtronic Vascular, Inc. $560 22 payments
  5. Edwards Lifesciences Corporation $123 3 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $100 6 payments
  7. Novartis Pharmaceuticals Corporation $97 5 payments
  8. Janssen Pharmaceuticals, Inc $91 5 payments
  9. Osprey Medical Inc $89 1 payment
  10. Biotronik Inc. $86 2 payments
  11. Other $318 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $279,626 136 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,688 4 payments
  3. Travel and Lodging $7,725 2 payments
  4. Food and Beverage $2,346 65 payments
Products named General payments · program years 2019–2025
  1. MITRACLIP Vascular $63,375 14 payments
  2. AMPLATZER Occluders Cardiac Arrhythmias and Heart Failure $49,823 47 payments
  3. AMPLATZER AMULET $41,750 17 payments
  4. MITRACLIP Structural Heart $41,750 16 payments
  5. JenaValve Pericardial TAVR System $30,425 11 payments
  6. AMPLATZER Occluders Structural Heart $10,750 8 payments
  7. JETI ALL IN ONE NON-STERILE KIT $9,500 4 payments
  8. MitraClip System $7,125 6 payments
  9. Clinical Trial Product Clinical Trial Product_IC $6,875 2 payments
  10. CLINICAL TRIAL PRODUCT Clinical Trial Product $6,813 6 payments
  11. Other $1,414 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Internal Medicine: 777

Drug cost

$77

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 13 $77

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record